en POLSKI
eISSN: 2544-2538
ISSN: 2450-8624
Pielęgniarstwo w Opiece Długoterminowej / Long-Term Care Nursing
Current issue Archive About the journal Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2022
vol. 7
 
Share:
Send email
Share:
Original paper

Assessment of the level of knowledge and attitudes of cancer patients in the field of vascular access such as intravenous port

Renata Piotrkowska
1
,
Piotr Jarzynkowski
1
,
Marcelina Bożejewicz
1
,
Katarzyna Kwiecień-Jaguś
2

  1. Zakład Pielęgniarstwa Chirurgicznego, Gdański Uniwersytet Medyczny Instytut Pielęgniarstwa i Położnictwa, Polska
  2. Zakład Pielęgniarstwa Anestezjologicznego i Intensywnej Opieki, Gdański Uniwersytet Medyczny Instytut Pielęgniarstwa i Położnictwa, Polska
Online publish date: 2022/08/28
Article file
- 2.pdf  [0.12 MB]
Get citation
 
 
1. Morris WJ, Tyldesley S, Rodda S et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing low-dose-rate brachytherapy boost to dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.
2. Tharmalingam H, Tsang Y, Choudhury A et al. External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 2020; 106: 525-533.
3. Dutta SW, Alonso CE, Libby B, Showalter TN. Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives. Expert Rev Med Devices 2018; 15: 71-79.
4. Hoskin PJ, Motohashi K, Bownes P et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007; 84: 114-120.
5. Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
6. Crook J, Marbán M, Batchelar D. HDR prostate brachytherapy. Semin Radiat Oncol 2020; 30: 49-60.
7. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41: 781-793.
8. Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology 2018; 85: 108-116.
9. Hentschel B, Oehler W, Strauß D et al. Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer. Strahlenther Onkol 2011; 187: 183-190.
10. Rasch C, Barillot I, Remeijer P et al. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57-66.
11. Salembier C, Villeirs G, De Bari B et al. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 2018; 127: 49-61.
12. Sanda MG, Cadeddu JA, Kirkby E et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 2018; 199: 683-690.
13. Sanda MG, Cadeddu JA, Kirkby E et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 2018; 199: 990-997.
14. Cellini N, Morganti AG, Mattiucci GC et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002; 53: 595-599.
15. Arrayeh E, Westphalen AC, Kurhanewicz J et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012; 82: e787-e793.
16. McNeal JE, Price HM, Redwine EA et al. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 1988; 139: 61-65.
17. Kerkmeijer LGW, Groen VH, Pos FJ et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 2021; 39: 787-796.
18. von Eyben FE, Kiljunen T, Kangasmaki A et al. Radiotherapy boost for the dominant intraprostatic cancer lesion – a systematic review and meta-analysis. Clin Genitourin Cancer 2016; 14: 189-197.
19. Pieters B, Wijkstra H, van Herk M et al. Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning. J Contemp Brachytherapy 2012; 4: 69-74.
20. Tissaverasinghe S, Crook J, Bachand F et al. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: a phase II randomized trial. Brachytherapy 2019; 18: 299-305.
21. Fischbach F, Hass P, Schindele D et al. MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: a feasibility study of focal radiation therapy (ProFocAL). Eur Radiol 2020; 30: 2072-2081.
22. Wang T, Press RH, Giles M et al. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy. Br J Radiol 2019; 92: 20190089.
23. Gomez-Iturriaga A, Casquero F, Urresola A et al. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial. Radiother Oncol 2016; 119: 91-96.
24. Lakosi F, Antal G, Pall J et al. HDR brachytherapy boost using MR-only workflow for intermediate- and high-risk prostate cancer: 8-year results of a pilot study. Brachytherapy 2021; 20: 576-583.
25. Mason J, Al-Qaisieh B, Bownes P et al. Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. Brachytherapy 2014; 13: 137-145.
26. Rodda S, Tyldesley S, Morris WJ et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.
27. Camarata AS, Nickleach DC, Jani AB, Rossi PJ. Locoregional prostate cancer treatment pattern variation in independent cancer centers: policy effect, patient preference, or physician incentive? Health Serv Insights 2015; 8: 1-8.
28. Orio PF, III, Nguyen PL, Buzurovic I et al. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys 2016; 96: 624-628.
29. Beuthien-Baumann B, Koerber SA. PET imaging in adaptive radiotherapy of prostate tumors. Q J Nucl Med Mol Imaging 2018; 62: 404-410.
30. Gaudreault M, Chang D, Hardcastle N et al. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clin Transl Radiat Oncol 2022; 35: 84-89.
31. Goodman CD, Fakir H, Pautler S et al. Dosimetric evaluation of PSMA PET-delineated dominant intraprostatic lesion simultaneous infield boosts. Adv Radiat Oncol 2020; 5: 212-220.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.